| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | -0.095 | 0.01 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.01 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.01 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.4 | 0.01 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |